Identification | Back Directory | [Name]
YLL545 | [CAS]
1423126-69-5 | [Synonyms]
YLL545 Urea, N-[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]-N′-[3-(trifluoromethyl)phenyl]- | [Molecular Formula]
C19H13F3N6O2 | [MOL File]
1423126-69-5.mol | [Molecular Weight]
414.34 |
Chemical Properties | Back Directory | [Boiling point ]
490.013±45.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.557±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
9.488±0.23(predicted) |
Hazard Information | Back Directory | [Uses]
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth[1]. | [References]
[1] Zhang J, et al. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget. 2016 Jul 5;7(27):41067-41080. DOI:10.18632/oncotarget.9392 |
|
|